Applicant(s)
VLASUK ET AL.
Art Unit
1653
heet with the correspondence address DSED in this application. If not included communication will be mailed in due course. THIS ation is subject to withdrawal from issue at the initiative
P(a)-(d) or (f). pplication No received in this national stage application from the
on to file a reply complying with the requirements tion.
hed EXAMINER'S AMENDMENT or NOTICE OF e oath or declaration is deficient.
g Review (PTO-948) attached ment or in the Office action of tten on the drawings in the front (not the back) of to 37 CFR 1.121(d).
L MATERIAL must be submitted. Note the Γ OF BIOLOGICAL MATERIAL.
tice of Informal Patent Application (PTO-152) erview Summary (PTO-413), aper No./Mail Date <u>9/30/04</u> . aminer's Amendment/Comment aminer's Statement of Reasons for Allowance her
id the second of

Application/Control Number: 09/498,556

Art Unit: 1653

DETAILED ACTION

Status of the Claims

Applicants' response to sequence compliance notice dated June 16, 2004, filed on July 19, 2004 is acknowledged. An amendment in response to office action dated December 31, 2003 filed on March 31, 2004 is also acknowledged. A supplemental amendment filed September 30, 2004 is also acknowledged. An amendment in the continuing data on page 1 of the specification has been noted and entered. Claims 1-282 have been canceled. New claims 283-295 have been added. Therefore, claims 283-295 are currently pending and under consideration.

Response to Amendments

The sequence compliance notice is withdrawn in view of Applicants response and remarks that in accordance with WIPO Standard ST.25 (1998), Formula III is not required to be placed in the Sequence Listing.

The rejection of claims 270-282 (now 283-295) under **35 U.S.C. 112, second paragraph** is withdrawn in view of applicants' amendment of the claims.

The rejection of claims 270-271 (now 283 and 284) under **Nonstatutory Double Patenting** over Patent NO: US 5864009 is withdrawn in view of the submission of the Terminal Disclaimer in compliance with 37 CFR 1.32(c).

Reasons for Allowance

The following is an examiner's statement of reasons for allowance:

The prior art of record does not teach or suggest a protein isolated from a Nematode species having anticoagulant activity and having one or more Nematode Anticoagulant Protein (NAP) domains, wherein the protein was isolated from *Ancyclostoma caninum* (designated as AcaNAPc2). Wherein each NAP domain includes the sequence of Formula III and wherein the amino acid sequence of AcaNAPc2 is set forth in SEQ ID NO: 59.

Application/Control Number: 09/498,556

Art Unit: 1653

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion

Claims 283-295 are allowed.

Inquiries

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Rita Mitra whose telephone number is (571) 272-0954. The Examiner can normally be reached from 9:30 a.m. to 6:30 p.m. on weekdays. If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Dr. Jon Weber, can be reached at (571) 272-0925. Papers related to this application may be submitted to Technology Center 1600 by facsimile transmission. Papers should be faxed to Technology Center 1600 via the PTO Fax Center. The faxing of such papers must conform with the notice published in the Official Gazette,1096 OG 30 (November 15, 1989). The Fax Center number is (703) 872-9306. Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (571) 272-0547.

Rita Mitra, Ph.D.

September 30, 2004

JON WEBER
SUPERVISORY PATENT EXAMINER